Bacteria

Ongoing clinical trials and approved products targeting Bacteria, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

5ongoing imaging trials

0approved products

Target note

Full name: Bacteria (specific metabolism)
Nature: Substrates taken up by bacteria and not by human cells: sorbitol, maltodextrins, antibiotics, siderophores.
Normal expression: Kidneys, urinary tract.
Value: Telling infection from sterile inflammation, which FDG cannot do.
Approaches: [18F]FDS (fluorodeoxysorbitol), [18F]fluoropropyl-trimethoprim, [68Ga] siderophores, labeled maltose.
Indications explored: Prosthetic infections, osteomyelitis, endocarditis, lung infections (research).
Points of caution: Bacterial spectrum specific to each tracer (Gram-negative for FDS).

Trial	Phase	Status	Sponsor	Countries
Bacterial tracers2024-515781-13-00 · Bacterial infections	Phase 2	Recruiting	Centre Hospitalier Universitaire De Bordeaux	1
Bacterial tracersNCT07704333 · Bacterial infections	Phase 1	Recruiting	National Institutes of Health Clinical Center (CC)	1
Bacterial tracersNCT04263792 · Bacterial infections	Phase 1	Recruiting	University of Pennsylvania	1
Bacterial tracersNCT07110519 · Healthy volunteers (dosimetry, biodistribution)	Phase 1	Active, not recruiting	St. Jude Children's Research Hospital	1
SORB-PET · Bacterial tracersNCT07760012 · Breast	No phase	Recruiting	Peking University Third Hospital	1

Bacteria. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/bacteria/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.